Related references
Note: Only part of the references are listed.Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma
Ho-Man Yeung et al.
JOURNAL OF GASTROINTESTINAL CANCER (2023)
Futibatinib for intrahepatic cholangiocarcinoma
Holly Baker
LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)
Genetic alterations of GI-NECs involving three main signaling pathways
Qiong Dai et al.
CANCER MEDICINE (2023)
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
Halfdan Sorbye et al.
JOURNAL OF NEUROENDOCRINOLOGY (2023)
Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas
Jennifer J. Gile et al.
JOURNAL OF NEUROENDOCRINOLOGY (2023)
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms
Hege Elvebakken et al.
JOURNAL OF NEUROENDOCRINOLOGY (2023)
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
Stian Knappskog et al.
JCO Precision Oncology (2023)
Bevacizumab plus FOLFIRI after failure of platinum- etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC) : a randomised, multicentre, non-comparative, open-label, phase 2 trial
Thomas Walter et al.
LANCET ONCOLOGY (2023)
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma
Melissa Frizziero et al.
CLINICAL CANCER RESEARCH (2022)
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Andreas Venizelos et al.
ENDOCRINE-RELATED CANCER (2022)
Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Shinichi Yachida et al.
CANCER DISCOVERY (2022)
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
T. Al-Toubah et al.
ESMO OPEN (2022)
Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
Amr Mohamed et al.
CANCERS (2022)
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
L. Paz-Ares et al.
ESMO OPEN (2022)
Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials
D. L. Chan et al.
EUROPEAN JOURNAL OF CANCER (2022)
NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
Mairead Geraldine McNamara et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Jennifer Rachel Eads et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).
David Bing Zhen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
M. C. Riesco Martinez et al.
ANNALS OF ONCOLOGY (2022)
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux et al.
ENDOCRINE-RELATED CANCER (2022)
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
Federico Longo-Munoz et al.
EUROPEAN JOURNAL OF CANCER (2022)
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial
Chigusa Morizane et al.
JAMA ONCOLOGY (2022)
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites
Thomas Yang Sun et al.
ENDOCRINE-RELATED CANCER (2022)
Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
Akihiro Ohmoto et al.
DISCOVER ONCOLOGY (2022)
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System The TOPIC-NEC Phase 3 Randomized Clinical Trial
Chigusa Morizane et al.
JAMA ONCOLOGY (2022)
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
Noritoshi Kobayashi et al.
CANCER SCIENCE (2021)
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms
James C. Yao et al.
ENDOCRINE-RELATED CANCER (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review
Tiziana Feola et al.
CANCERS (2021)
SWOG S1609-A phase 2 basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors: A high-grade neuroendocrine neoplasm cohort
Sandip Pravin Patel et al.
CANCER (2021)
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin
Julien Hadoux et al.
DIGESTIVE AND LIVER DISEASE (2021)
Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms Mayo Clinic Experience
Jennifer J. Gile et al.
PANCREAS (2021)
Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
N. Girard et al.
ANNALS OF ONCOLOGY (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
David L. Chan et al.
ONCOLOGIST (2021)
Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Jaume Capdevila et al.
CLINICAL CANCER RESEARCH (2020)
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P. Patel et al.
CLINICAL CANCER RESEARCH (2020)
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Ming Lu et al.
CLINICAL CANCER RESEARCH (2020)
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Halfdan Sorbye et al.
ENDOCRINE-RELATED CANCER (2020)
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)
Hiroyuki Okuyama et al.
NEUROENDOCRINOLOGY (2020)
EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms
Stefan Munker et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2020)
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
Namrata Vijayvergia et al.
BRITISH JOURNAL OF CANCER (2020)
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang et al.
CANCER (2020)
Blood-based next-generation sequencing analysis of neuroendocrine neoplasms
Katerina Zakka et al.
Oncotarget (2020)
Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma
Patrick W. McGarrah et al.
PANCREAS (2020)
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Oliver Klein et al.
CLINICAL CANCER RESEARCH (2020)
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Alberto Puccini et al.
CLINICAL CANCER RESEARCH (2020)
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
Alberto Bongiovanni et al.
BMJ OPEN (2020)
Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
Mairead G. McNamara et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Esben Andreas Carlsen et al.
ENDOCRINE-RELATED CANCER (2019)
Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
Claire Mulvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).
Christian Fottner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
Nataliya Volodymyrivna Uboha et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
1400PEfficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
L Apostolidis et al.
ANNALS OF ONCOLOGY (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Anna Pellat et al.
NEUROENDOCRINOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases
Arvind Dasari et al.
CANCER (2018)
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T. Walter et al.
EUROPEAN JOURNAL OF CANCER (2017)
Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma
Norimitsu Kasahara et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
P1-3-4Amrubicin therapy for platinum-refractory extrapulmonary neuroendocrine carcinoma: Retrospective single-center analysis
Yukako Hattori et al.
ANNALS OF ONCOLOGY (2016)
Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma
T. Ebata et al.
ANNALS OF ONCOLOGY (2016)
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract
Tomonori Araki et al.
ANTI-CANCER DRUGS (2016)
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat et al.
ONCOLOGIST (2016)
BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy
Samuel J. Klempner et al.
CANCER DISCOVERY (2016)
Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
Leonidas Apostolidis et al.
CANCER MEDICINE (2016)
Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites
Emily K. Bergsland et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J. Hadoux et al.
ENDOCRINE-RELATED CANCER (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum
James D. Smith et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
Tomohiro Yamaguchi et al.
CANCER SCIENCE (2014)
Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
Ingrid Holst Olsen et al.
JOURNAL OF CANCER (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3
O. Hentic et al.
ENDOCRINE-RELATED CANCER (2012)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
Ingrid H. Olsen et al.
SCIENTIFIC WORLD JOURNAL (2012)
Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
Staffan Welin et al.
CANCER (2011)
Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms
Guenter Kloeppel
ENDOCRINE-RELATED CANCER (2011)